ALKERMES | ALKS - Cash And Equivalent

Stock Price
37.48
Daily Change
-0.88 -2.29%
Monthly
11.00%
Yearly
19.29%
Q2 Forecast
36.35

ALKERMES reported $351.55M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Malin Corporation EUR 62.1M 26.4M Dec/2024
Merck USD 5.33B 9.24B Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Otsuka Holdings JPY 534.64B 123.53B Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026